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The increased use of bioprostheses in aortic valve replacement has led to 
increased number of patients with structural valve degeneration. Since reoperation 
for failed bioprostheses carries a high risk, a valve-in-valve transcatheter aortic 
valve replacement has become an attractive alternative treatment. However, there 
remains technical challenges and controversies in this field. Herein, we discuss the 
current perspectives in valve-in-valve transcatheter aortic valve replacement.
Keywords: transcatheter aortic valve replacement, valve-in-valve, failed 
bioprostheses
1. Introduction
The use of bioprosthetic valves in aortic valve replacement (AVR) has been 
increasing, even in younger patients [1]. In the meantime, the indication of 
transcatheter aortic valve replacement (TAVR) has been expanding as well. Since 
reoperation for degenerated prosthetic valve carries a high risk, a valve-in-valve 
TAVR has become an attractive alternative treatment. The most recent guide-
lines stated that valve-in-valve TAVR is recommended as class IIa indication for 
“severely symptomatic patients with bioprosthetic aortic valve stenosis judged 
by the heart team to be at high or prohibitive risk of reoperation, and in whom 
improvement in hemodynamics is anticipated” [2]. However, technical challenges 
exist in valve-in-valve TAVR. In this chapter, we discuss the current perspective of 
valve-in-valve TAVR and its associated risks and benefits.
2. Indications of valve-in-valve TAVR
2.1 Outcomes of redo aortic valve replacement
The use of bioprosthetic valve in AVR has been expanding. That will inevitably 
lead to increased number of patients who need re-aortic valve replacement for 
degenerated bioprostheses. Redo aortic valve replacement carries a higher operative 
risk compared to primary aortic valve replacement.
Kaneko et al. investigated 3,380 patients from The Society of Thoracic Surgeons 
database who underwent elective, isolated redo aortic valve replacement (AVR) 
after a previous AVR [3]. The operative mortality was 4.6%, and the incidence of 
Interventional Cardiology
2
Study Year Number 
of pts
Key outcomes
Dvir et al. [4] 2014 459 Thirty-day mortality; 7.6%.
Thirty-day stroke rate; 1.7%.
One-year survival rate; 83.2%.
Patients who had stenosis had worse 
1-year survival in comparison with 
regurgitation.
Patients with small valves had worse 
1-year survival in comparison with 
intermediate or large valves.
Tuzcu et al. [5] 2018 1150 Thirty-day mortality; 2.9%.
Thirty-day stroke rate; 1.7%.
Thirty-day heart failure 
hospitalization rate; 2.4%.
One-year survival rate; 88.3%.
Patients in the valve-in-valve TAVR 
group had higher post-TAVR mean 
gradient, but less moderate or severe 
aortic regurgitation compared to 
native-valve TAVR group.
Post-TAVR gradients were highest in 
small SAVRs and stenotic SAVRs.
Webb et al. [6] 2017 365 Thirty-day mortality; 2.7%.
Thirty-day stroke rate; 2.7%.
One-year survival rate; 87.6%.
Mean transaortic gradient was 
17.6 mm Hg, and effective orifice area 
was 1.16 cm2 at 1 year.
Webb et al. [7] 2019 365 Three-year survival rate; 67.3%
Aortic valve re-replacement was 
required in 1.9%.
Mean transaortic gradient was 
16.6 mm Hg at 3-year follow-up.
Effective orifice area was 1.15 cm2 at 
3-year follow-up.
Moderate to severe aortic 
regurgitation was 2.5% at 3 years.
New York Heart Association 
functional class improved, with 
90.4% in class III or IV at baseline 
and 14.1% at 3 years.
Neupane et al. [8] 2018 227 Thirty-day mortality; 5%.
Thirty-day major stroke rate; 2%.
Permanent pacemaker implantation; 
9%.
Valve-in-valve TAVR and re-SAVR 
had similar thirty-day mortality, and 
similar rates of stroke, myocardial 
infarction, and acute kidney injury 
requiring dialysis.
Pibarot et al. [16] 2018 1168 Thirty-day mortality; 10.3% in severe 
PPM, 4.3% in no or moderate PPM.
Adjusted one-year survival rate; 
80.7% in severe PPM, 89.1% in no or 
moderate PPM.
Patients with pre-existing severe 
PPM more frequently harbored high 
post-procedural gradients.
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mortality, morbidity, stroke, postoperative aortic insufficiency mild or greater, 
pacemaker implantation and vascular complications was higher in redo AVR group 
compared to primary AVR patients.
2.2 Outcomes of valve-in-valve TAVR
Overall the outcomes of valve-in-valve TAVR have been reported to equivalent 
or better compared to those of redo surgical AVR.
The Valve-in-Valve International Data (VIVID) reported the outcomes of valve-
in-valve TAVR for 459 patients in 55 centers [4]. The thirty-day mortality was 7.6%. 
Overall one-year survival rate was 83.2% Patients with bioprosthetic stenosis had 
worse 1-year survival compared with the patients with bioprosthetic regurgitation. 
Patients with small valves had worse 1-year survival compared to intermediate or 
large valves.
Study Year Number 
of pts
Key outcomes
Deeb et al. [26] 2017 227 Thirty-day mortality; 2.2%.
Thirty-day major stroke rate; 0.4%.
One-year survival rate; 85.4%.
Moderate aortic regurgitation 
occurred in 3.5% of patients at 
30 days and 7.4% of patients at 1 year, 
with no severe aortic regurgitation.
The rate of new permanent 
pacemaker implantation was 8.1% at 
30 days and 11.0% at 1 year.
The mean valve gradient was 
17.0 ± 8.8 mm Hg at 30 days and 
16.6 ± 8.9 mm Hg at 1 year.
Factors significantly associated 
with higher discharge mean aortic 
gradients were surgical valve size, 
stenosis as modality of surgical valve 
failure, and presence of surgical valve 
prosthesis patient mismatch.
de Freitas Campos 
Guimarães et ak [27]
2018 116 Thirty-day mortality; 6.9%.
Three-year survival rate; 74.1%.
Average mean transaortic gradients 
remained stable up to 5-year 
follow-up.
Clinically relevant structural valve 
degeneration occurred in 3%, and 
15.1% had subclinical structural valve 
degeneration.
Goztek et al. [28] 2018 342 Thirty-day mortality; 5.4%.
Permanent pacemaker implantation; 
6.8%.
Valve-in-valve TAVR was associated 
with higher incidence of PPM, higher 
paravalvular leaks and higher mean 
postoperative aortic valve gradients 
compared to re-SAVR.
TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replacement; PPM: prosthesis-patient 
mismatch.
Table 1. 
Previous studies which reported the clinical outcomes of valve-in-valve TAVR.
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The Transcatheter Valve Therapy (TVT) Registry showed that unadjusted 
30-day mortality after valve-in-valve TAVR was 2.9%, and it was better than that of 
native valve TAVR (4.8%) [5].
The PARTNER (Placement of Aortic Transcatheter Valves) 2 trial showed that 
30-day mortality was 2.7%, stroke was 2.7%, major vascular complication was 4.1%, 
conversion to surgery was 0.6%, coronary occlusion was 0.8%, new pacemaker 
insertion was 1.9%, and one year all-cause mortality was 12.4% [6]. Recently 3-year 
outcomes after valve-in-valve TAVR in the Partner 2 registry was published [7]. 
The mean age of the patients was 78.9 ± 10.2 years. At 3 years, the estimate all-cause 
mortality was 32.7%. Quality of life of the patients improved compared to baseline.
Neupane et al. conducted a meta-analysis of the previously reported studies to 
determine outcomes after valve-in-valve TAVR and redo AVR [8]. Their analysis 
showed no difference in 30-day mortality between valve-in-valve TAVR and redo 
AVR for failed bioprosthetic aortic valve.
Previous studies which reported the clinical outcomes of valve-in-valve TAVR 
are listed in Table 1.
3. Complications in valve-in-valve TAVR
3.1 Prosthesis-patient mismatch
Valve-in-valve TAVR could cause prosthesis-patient mismatch especially when 
there was severe bioprosthetic valve stenosis. It was also pointed out that valve-
in-valve TAVR was an independent predictor of valve hemodynamic deterioration 
(defined as an increase in mean aortic valve gradient ≥10 mm Hg) [9].
Herrmann et al. reviewed 62,125 patients in the Society of Thoracic Surgeons/
American College of Cardiology TVT registry and reported that severe prosthesis-
patient mismatch occurred in 12% [10]. Patients with severe prosthesis-patient 
mismatch had higher mortality rate compared to patients with moderate or no 
prosthesis-patient mismatch.
On the contrary, Dvir et al. reported that severe prosthesis-patient mismatch 
occurred in 31.8% of patients surviving aortic valve-in-valve TAVR [4]. However, 
one-year survival was not affected by having severe prosthesis-patient mismatch.
The long-term transaortic gradient has not been reported. In the Partner II 
registry, mean transaortic gradient was 16.6 mmHg at 3-year follow-up [7].
3.2 Coronary obstruction
Coronary obstruction is a rare, but life-threatening complication associated 
with TAVR. Its incidence in native valve TAVR was reported as less than 1% [11]. 
However, it occurs more frequently in valve-in-valve TAVR.
Ribeiro et al. reviewed 1,612 patients from the Valve-in-Valve International Data 
Registry [12]. Coronary obstruction occurred in 37 patients (2.3%), and the 30-day 
mortality was 52.9% among the patients who had coronary obstruction. Coronary 
obstruction happened more frequently in stented valves with externally mounted 
leaflets or stentless valves compared to stented valves with internally mounted 
leaflets.
Multiple detector computed tomography is a standard diagnostic modality in the 
planning of TAVR [13]. A virtual transcatheter valve to coronary ostium distance 
<4 mm is considered a high risk of coronary obstruction [12].
In the case of anticipated high risk of coronary obstruction, a placement of 
a coronary guidewire with coronary balloon or undeployed stent in the targeted 
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coronary arteries before deploying TAVR is a good option for coronary protection, 
since the emergent percutaneous coronary intervention for coronary obstruction 
is challenging. Ribeiro et al. reported that percutaneous coronary intervention was 
successful only in 81.8% [11].
Delayed coronary obstruction is a rare complication following TAVR that 
accompanies with high in-hospital mortality. Jabbour et al. reported that the inci-
dence of delayed coronary obstruction was 0.22% in 17,092 TAVR procedures and 
the overall in-hospital mortality was 50% [14]. Percutaneous coronary interven-
tion was successful only in 68.8%. It occurred more frequently after valve-in-valve 
TAVR compared to native valve TAVR (0.89% vs. 0.18%) and it occurred more 
frequently in self-expandable valves compared to balloon-expandable valves 
(0.36% vs. 0.11%).
3.3 Self-expandable valve versus balloon-expandable valve
Self-expanding valves are usually associated with lower postprocedural 
gradients. Rogers et al. reported that hemodynamics of self-expandable valves 
were superior to that of balloon-expandable valves in patients with small aortic 
annulus [15].
In the meantime, Dvir et al. reported that elevated postprocedural gradients 
were happened more frequently in balloon expandable valves compared with self-
expandable valves [4].
Pibarot et al. reported that pre-existing prosthesis-patient mismatch of the 
failed surgical valve was strongly and independently associated with increased risk 
for mortality following valve-in-valve TAVR [16]. Elevated pressure gradients are 
seen in more than 70% of patients who present with baseline prosthesis-patient 
mismatch if treated with balloon-expandable valves.
The optimal deployment height would be important to avoid postprocedural 
high gradients. Simonato et al. reported that lower gradients and greater effective 
orifice areas were achieved with higher deployment positions than lower deploy-
ment in vitro study [17]. Hatoum et al. reported that supra-annular axial deploy-
ment is associated with lower pressure gradients, and sub-annular deployment is 
associated with more favorable sinus hemodynamics [18].
When severe prosthesis-patient mismatch is present, a self-expanding device 
in a supra-annular position would be the preferred treatment strategy. Dvir et al. 
suggested an implant depth of up to 3 mm for the self-expandable valve; Evolut 
(Medtronic, Minneapolis, Minnesota), and up to 20% frame depth for the balloon-
expandable valve; SAPIEN 3 (Edwards Lifesciences, Irvine, California) [19].
3.4 Structural valve deterioration after TAVR
Bioprosthetic valve dysfunction happens both in surgical AVR and TAVR. 
However, bioprosthetic valve dysfunction is a broad term that encompasses struc-
tural and non-structural valve deterioration [20]. It is very important to distinguish 
between two of them. Structural valve deterioration is the principal etiological 
factor, and it can lead to irreversible valve dysfunction, whereas non-structural 
valve deterioration includes reversible dysfunction such as valve thrombosis or 
endocarditis.
The long-term durability of valve-in-valve TAVR has been unknown. One of 
the longest follow-up data was reported from Partner II registry [7]. Among 337 
patients who could be followed for 3 years, 5 patients underwent repeat aortic 
valve replacement for aortic valve dysfunction after valve-in-valve procedure. 
Moderate hemodynamic valve deterioration occurred in 2 out of 160 patients 
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(1.3%), and severe hemodynamic valve deterioration also occurred in 2 out of 
160patients (1.3%) at 3 years.
3.5 Valve thrombosis
Valve thrombosis following TAVR has been increasingly recognized. Valve 
thrombosis is associated with reduced leaflet motion, and leads to high chance of 
strokes and transient ischemic attacks. Subclinical leaflet thrombosis is manifested 
by either hypo-attenuated leaflet thickening or reduced leaflet motion [21].
Del Trigo et al. reported that the incidence of valve hemodynamic deterioration 
following TAVR was 4.5% in 1,521 patients, and a valve-in-valve procedure was an 
independent predictor for valve hemodynamic deterioration [22].
Vahidkhah et al. analyzed computational three-dimensional models for the 
surgical aortic valve and transcatheter aortic valve [23]. They found that geometric 
confinement of the transcather aortic valve by the leaflets and the frame of the 
degenerated bioprosthesis that circumferentially surround the transcatheter aortic 
valve stent increased the blood residence time on the leaflets, which could act as a 
permissive factor in the leaflet thrombosis after valve-in-valve TAVR.
3.6 Antiplatelet/anticoagulation therapy after TAVR
The optimal antiplatelet/anticoagulation management after TAVR has been 
controversial [20, 24].
Most of the societies such as American Heart Association and Society of 
Thoracic Surgeons recommend lifelong-aspirin and 6 months of Clopidogrel after 
TAVR. In terms of anticoagulant therapy, it may be considered in patients with 
chronic atrial fibrillation or other indications. Vitamin K antagonist may be consid-
ered in the first 3 months after procedure in patients at risk for atrial fibrillation or 
valve thrombosis.
Overtchouk et al. reviewed 11,469 patients in French registry, and found that 
anticoagulation decreased the risk of bioprosthetic valve dysfunction, whereas 
chronic renal failure and prosthesis size ≤23 mm were associated with the risk of 
bioprosthetic valve dysfunction [25].
4. Conclusions
The valve-in-valve TAVR has provided satisfactory outcomes for degenerative 
bioprosthetic aortic valve. It is recommended with class IIa indication in high risk 
patients for redo surgical AVR. However, physicians need to understand techni-
cal challenges in valve-in-valve TAVR such as residual high pressure gradient, 
prosthesis-patient mismatch and coronary obstruction. The long-term durability 
of valve-in-valve procedure remains unknown. Moreover, anticoagulation manage-
ment and superiority between self-expandable and balloon-expandable valves have 
been controversial.
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